Overview

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT

Status:
Unknown status

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

1. Primary endpoint: Time to relapse/progression (TTP) after achieving a complete or partial response with the (R-GemOxD)-induction therapy 2. Secondary endpoints: 1. Quality of response obtained after subcutaneous Rituximab maintenance. 2. Progression-Free Survival (PFS) 3. Overall Survival (OS) 4. Time to Next Therapy (TTNT) 5. Value of MRD in the disease outcome 6. Toxicity

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Treatments:

Rituximab